For the quarter ending 2025-09-30, RGNX has $525,203K in assets. $363,751K in debts. $58,802K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 58,802 | 79,558 | ||
| Marketable securities | 215,403 | 243,740 | ||
| Accounts receivable | 25,347 | 20,199 | ||
| Prepaid expenses | 12,943 | 10,776 | ||
| Other current assets | 19,472 | 19,479 | ||
| Total current assets | 331,967 | 373,752 | ||
| Marketable securities | 27,838 | 40,296 | ||
| Accounts receivable | 2,765 | 1,584 | ||
| Total property and equipment | 191,054 | - | ||
| Accumulated depreciation and amortization | 83,539 | - | ||
| Property and equipment, net | 107,515 | 111,017 | ||
| Operating lease right-of-use assets | 48,820 | 50,469 | ||
| Restricted cash | 2,030 | 2,030 | ||
| Other assets | 4,268 | 1,879 | ||
| Total assets | 525,203 | 581,027 | ||
| Accounts payable | 22,266 | 21,655 | ||
| Accrued expenses and other current liabilities | 38,316 | 35,557 | ||
| Deferred revenue | 13,195 | 13,977 | ||
| Operating lease liabilities | 9,073 | 8,049 | ||
| Royalty monetization liabilities | 41,718 | 40,302 | ||
| Total current liabilities | 124,568 | 119,540 | ||
| Deferred revenue | 21,186 | 23,804 | ||
| Operating lease liabilities | 67,433 | 69,647 | ||
| Royalty monetization liabilities | 149,916 | 153,693 | ||
| Other liabilities | 648 | 664 | ||
| Total liabilities | 363,751 | 367,348 | ||
| Common stock 0.0001 par value 100,000 shares authorized at september 30, 2025 and december 31, 2024 50,619 and 49,549 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 5 | 5 | ||
| Additional paid-in capital | 1,220,977 | 1,211,361 | ||
| Accumulated other comprehensive loss | -652 | -750 | ||
| Accumulated deficit | -1,058,878 | -996,937 | ||
| Total stockholders equity | 161,452 | 213,679 | ||
| Total liabilities and stockholders equity | 525,203 | 581,027 | ||
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)